Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing
Gerjon J Ikink1, John Hilkens1
1Division of Molecular Genetics, The Netherlands Cancer Institute , Amsterdam, the Netherlands.
Molecular & Cellular Oncology
|April 13, 2017
Abstract:
Insulin receptor substrate 4 (IRS4) belongs to a family of cytoplasmic docking proteins mediating signals from cell surface receptors to downstream effectors. While IRS1 and IRS2 mediate signals from an active receptor, we found that IRS4 hyperactivates the phosphatidylinositol phosphate kinase (PI3K)-pathway independent of upstream signals and is irresponsive to feedback regulation causing cancer and resistance to human epidermal growth factor receptor 2 (HER2) targeted therapy.
Insights
Insulin receptor substrate 4 (IRS4) hyperactivates the PI3K pathway independently of signals. This dysregulation contributes to cancer and HER2 therapy resistance.
Area of Science:
- Cellular signaling pathways
- Molecular biology
- Cancer research
Background:
- Insulin receptor substrates (IRS) are key docking proteins in cellular signal transduction.
- IRS1 and IRS2 transmit signals downstream from activated cell surface receptors.
- The specific role of IRS4 in signaling and its clinical implications remain less understood.
Purpose of the Study:
- To investigate the signaling mechanism of Insulin receptor substrate 4 (IRS4).
- To determine the role of IRS4 in cancer development and therapy resistance.
- To elucidate IRS4's unique activation and regulation compared to IRS1 and IRS2.
Main Methods:
- Analysis of IRS4's interaction with the PI3K pathway.
- Assessment of IRS4's signaling activity independent of upstream receptor activation.
- Investigation of feedback regulation mechanisms on IRS4.
- Evaluation of IRS4's contribution to cancer cell proliferation and resistance to HER2-targeted therapy.
Main Results:
- IRS4 was found to hyperactivate the phosphatidylinositol phosphate kinase (PI3K) pathway.
- IRS4 activation is independent of upstream receptor signaling.
- IRS4 exhibits irresponsiveness to feedback regulation.
- This aberrant IRS4 activity is linked to cancer and resistance to HER2-targeted therapy.
Conclusions:
- IRS4 acts as a unique, constitutively active signaling molecule.
- IRS4's dysregulation drives oncogenesis and therapeutic resistance.
- Targeting IRS4 may offer a novel strategy for cancer treatment.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:31Regulation of the Unfolded Protein Response
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...